Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial.
Jennifer L SherrBruce W BodeGregory P ForlenzaLori M B LaffelMelissa J SchoelwerBruce A BuckinghamAmy B CriegoDaniel J DeSalvoSarah A MacLeishDavid W HansenTrang T Lynull nullJennifer L SherrKate WeymanEileen TichyMichelle VanNameMichelle BreiMelinda ZgorskiAmy SteffenLori CarriaBruce W BodeAnna BusbyGregory P ForlenzaR Paul WadwaRobert SloverErin CobryLaurel MesserLori M LaffelElvira IsganaitisLouise Ambler-OsbornEmily FreinerChristine TurcotteLisa VolkeningMelissa SchoelwerSue A BrownKatie KrauthauseEmma EmoryMary OliveriBruce A BuckinghamLaya EkhlaspourRyan KingmanAmy B CriegoBetsy L SchwartzLaura M GandrudAimee GriemeJamie HyattDaniel J DeSalvoSiripoom McKayKylie DeLaOCarolina VillegasSarah A MacLeishJamie R WoodBeth A KaminskiTerri CaseyWendy CampbellKim BehmRamon AdamsDavid W HansenSheri L StoneSuzan BzdickJane BulgerLynn AgostiniSarah DoolittleKaisa KivilaidKrista KleveTrang T LyBonnie DumaisTodd VienneauLauren M HuyettJoon Bok LeeJason O'ConnorEric BenjaminPublished in: Diabetes care (2022)
Use of the automated insulin delivery system was safe, and participants experienced improved glycemic measures and reduced hypoglycemia during the study phase compared with baseline.